Aktis Oncology, Inc. 8-K

What Happened
Aktis Oncology, Inc. (AKTS) filed a Form 8-K on May 11, 2026 (Item 2.02) to announce its financial results and business highlights for the quarter ended March 31, 2026. The company furnished a press release dated May 11, 2026 as Exhibit 99.1. The report was signed by Chief Financial Officer Kyle Kuvalanka.

Key Details

• Filing date: May 11, 2026 (Form 8-K, Item 2.02 and Item 9.01).
• Subject: Press release announcing financial results and business highlights for the quarter ended March 31, 2026 (Exhibit 99.1).
• Exhibit: Press release (Exhibit 99.1) was furnished with the 8-K; interactive XBRL cover page also included.
• Authorized signatory: /s/ Kyle Kuvalanka, Chief Financial Officer.

Why It Matters
This 8-K notifies investors that Aktis has publicly released its quarterly results and operating updates; those details (earnings, revenue, cash position, and business developments) will be in the furnished press release and any accompanying financial statements. Retail investors should review Exhibit 99.1 and subsequent SEC filings for the specific numbers and any operational or clinical updates that could affect the stock.